Aulitzky W., Gastl G., Aulitzky W.E., Nachbaur K., Lanske B., Kemmler G., Flener R., Frick J., Huber C. 1987. Interferon-gamma for the treatment of metastatic renal cancer: dose-dependent stimulation and downregulation of beta-2 microglobulin and neopterin responses. Immunobiology 176: 85-95.
Bachleitner-Hofmann T., Friedl J., Hassler M., Hayden H., Dubsky P., Sachet M., Rieder E., Pfragner R., Brostjan C., Riss S., Niederle B., Gnant M., Stift A. 2009.
Pilot trial of Autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma.Oncol Rep 21:1585–1592.
Banchereau J., Steinman R.M. 1998. Dendritic cells and the control of immunity. Nature 392: 245-252.
Bellone G., Novarino A., Vizio B., Brondino G., Addeo A., Prati A., Giacobino A., Campra D., Fronda G.R., Ciuffreda L. 2009. Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy. Int J Oncol 34:1701-1715.
Beverley P. 1996. Tumor Immunology, pp273-284, in Immunology 5th ed. Roitt I., Brostoff J., Male D. eds., Mosby, London.
Black P.L., Phillips H., Tribble H.R., Pennington R., Schneider M., Talmadge J.E. 1993.
Antitumor response to recombinant murine interferon gamma correlates with enhanced immune function of organ-associated, but not recirculating cytolytic T lymphocytes and macrophages. Cancer Immunol Immunother 37: 299-306.
Bonnefont-Rebeix C., de Carvalho C.M., Bernaud J., Chabanne L.,Marchal T., Rigal D.
2006. CD86 molecule is a specific marker for canine monocyte-derived dendritic cells. Vet Immunol Immunopathol 109:167–76.
Capobianco A., Querini P.R., Rugarili C., Manfredi A.A. 2006. Melanoma cells interfere with the interaction of dendritic cells with NK/LAK cells. Int J Cancer 119:
2861-2869.
Chapoval A.I., Tamada K., Chen L. 2000. In vitro growth inhibition of a broad spectrum of tumor cell lines by activated human dendritic cells. Blood 95: 2346-2351.
Chen L.K., Tourvieille B., Burns G.F., Bach F.H., Mathieu-Mahul D., Sasportes M., Bensussan A. 1986. Interferon: A cytotoxic T lymphocyte differentiation signal.
Eur J Immunol 16: 767-770.
Clark W.H., Elder D.E., Guerry D., Braitman L.E., Trock B.J., Schultz D., Synnestvedt M., Halpern A.C. 1989. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 81:1893-1904.
Couanet D.V., Leboulaire C., Maincent K., Toumier M., Hartmann O., Benard J., Beaujean F., Boccaccio C., Zitvogel L., Angevin E. 2002. Dendritic cells for NK/LAK activation: Rationale for multicellular immunotherapy in neuroblastoma patiants. Blood 100: 2554-2561.
Coussens L., Werb Z. 2002. Inflammention and cancer. Nature 420: 860-867.
Cowgill L.D., Spangler W.L. 1981. Renal insufficiency in geriatric dogs. Vet Clin North Am Small Anim Pract 11: 727-748.
Curti A., Tosi P., Comoli P., Terragna C., Ferri E., Cellini C., Massaia M., D'Addio A., Giudice V., Di Bello C., Cavo M., Conte R., Gugliotta G., Baccarani M., Lemoli R.M. 2007. Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using
patient-specific tumour idiotypeprotein or idiotype (VDJ)-derived class I restricted peptides. Br J Haematol 139: 415–424.
Dave S.S., Wright G., Tan B., Rosenwald A., Gascoyne R.D., Chan W.C., Fisher R.I., Braziel R.M., Rimsza L.M., Grogan T.M., Miller T.P., LeBlanc M., Greiner T.C., Weisenburger D.D., Lynch J.C., Vose J., Armitage J.O., Smeland E.B., Kvaloy S., Holte H., Delabie J., Connors J.M., Lansdorp P.M., Ouyang Q., Lister T.A., Davies A.J., Norton A.J., Muller-Hermelink H.K., Ott G., Campo E., Montserrat E., Wilson W.H., Jaffe E.S., Simon R., Yang L., Powell J., Zhao H., Goldschmidt N., Chiorazzi M., Staudt L.M. 2004. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351: 2159- 2169.
de Visser K.E., Eichten A., Couscens L.M. 2006. Paradoxical role of the immune system during cancer development. Nat Rev Cancer 6: 24-37.
Djeu J.Y., Stocks N., Zoon K., Stanton G.J., Timonen T., Herberman R.B. 1982. Positive self regulation of cytotoxicity in human natural killer cells by production of
interferon upon exposure to influenza and herpes viruses. J Exp Med 156:
1222-1234.
Dong H., Strome S.E., Salomao D.R., Tamura H., Hirano F., Flies D.B., Roche P.C., Lu J., Zho G., Tamada K., Lennon V.A., Celis E., Chen L. 2002. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 8: 793-800.
Engell-Noerregaard L., Hansen T.H., Andersen M.H., Thor Straten P., Svane I.M. 2009.
Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 58:1–14.
Fong L., Engleman E. 2000. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 18: 245-273.
Frasca L., Nasso M., Spensieri F., Fedele G., Palazzo R., Malavasi F., Ausiello C.M.
2008. J Immunol 180:1471-1481.
Galkowska H., Waldemar L.O., Wojewodzka U. 1996. Reactivity of antibodies directed against human antigens with surface markers on canine leukocytes.Vet Immunol Immunopathol 53:329-34.
Gao Q., Qiu S.J., Fan J., Zhou J., Wang X.Y., Xiao Y.S., Xu Y., Li Y.W., Tang Z.Y.
2007. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25: 2586-2593.
Geiger J.D., Huchinson R.J., Hohenkirk L.F., McKenna E.A., Yanik G.A., Levine J.E., Chang A.E., Braun T.M., Mule J.J. 2001. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 61:8513-8519.
Griffith T.S., Wiley S.R., Kubin M.Z., Sedger L.M., Maliszewski C.R., Fanger N.A.
1999. Monocyte-mediated Tumoricidal Activity via the Tumor Necrosis Factor–related Cytokine, TRAIL. J Exp Med 189: 1343-1353.
Gyorffy S., Rodriguez-Lecompte J.C., Woods J.P., Foley R., Kruth S., Liaw P.C., Gauldie J. 2005. Bone marrow-derived dendritic cell vaccination of dogs with naturally occurring melanoma by using human gp100 antigen. J Vet Intern Med 19:
56-63.
He T., Tang C., Xu S., Moyana T., Xiang J. 2007. Interferon gamma stimulates cellular maturation of dendritic cell line DC2.4 leading to induction of efficient cytotoxic T cell responses and antitumor immunity. Cell Mol Immunol 4:105-111.
Höltl L., Zelle-Rieser C., Gander H., Papesh C., Ramoner R., Bartsch G., Rogatsch H., Barsoum A.L., Coggin J.H. Jr., Thurnher M. 2002. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 8: 3369-3376
Homma S., Kikuchi T., Ishiji N., Ochiai K., Takeyama H., Saotome H., Sagawa Y., Hara E., Kufe D., Ryan JL., Ohno T., Toda G. 2005. Cancer immunotherapy by fusions of dendritic and tumour cells and rh-IL-12. Eur J Clin Invest 35: 2792-86.
Hori S., Heike Y., Takei M., Maruyama M., Inoue Y., Je-Jung L. 2004. Freeze-thawing procedures have no influence on the phenotypic and functional development of dendrite cells generated from peripheral blood CD14+ monocots. J Immunol 27:
27-35.
Horton H.M., Dorigo O., Hernandez P., Anderson D., Berek J.S., Parker S.E. 1999. IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile. J Immunol 163: 6378-6385.
Ibisch C., Pradal G., Bach J., Lieubeau B. 2005. Functional canine dendritic cells can be generated in vitro from peripheral blood mononuclear cells and contain a
cytoplasmic ultrastructural marker. J Immunol Methods 298: 175-182.
Inaba K., Inaba M., Romani N., Aya H., Deguchi M., Ikehara S., MuramatsuS., Steinman R.M. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony stimulating factor. J Exp Med 176: 1693-1702.
稲葉 カヨ、稲葉 宗夫、斉藤 敦、古江 増隆、垣内 史堂、中野 英樹. 2000. 樹 状細胞の基礎 pp.1-34 In:樹状細胞:基礎から応用へ (稲葉 カヨ、瀧川 雅浩 編). 南江堂、東京.
Ito T., Amakawa R., Inaba M., Ikehara S., Inaba K,. Fukuhara S. 2001. Differential regulation of human blood dendritic cell subsets by IFNs. J Immunol 166: 2961- 2969.
岩井 浤． 2001. 免疫の概説 pp.2-7 動物の免疫学 第二版（小沼 操、小 野寺 節、山内 一也 編）．文永堂出版、東京．
Janjic B.M., Lu G., Pimenov A., Whiteside T.L., Storkus W.J., Vujanovic N.L. 2002.
Innate direct anticancer effector function of human immature dendritic cells. I.
Involvement of an apoptosis-inducing pathway. J Immunol 168: 1823-1830.
Kammula U.S., Marincola F.M. 1999. Cancer immunotherapy: is there real progress at last? Bio Drugs 11:249-260.
Kasza L. 1994. Establishment and characterization of canine thyroid adenocarcinoma cell lines. Am J Vet Res 25:1178–1185.
Kato M., Goto S., Soma G. 2010. Lymphokine-activated killer cell therapy combined with high-dose glucocorticoid showed clinical efficacy towards advanced lung carcinoma. Anticancer Res 30: 3125-3128.
Kim J.H., Lee Y., Bae Y.S., Kim W.S., Kim K., Im H.Y., Kang W.K., Park K., Choi H.Y., Lee H.M., Baek S.Y., Lee H., Doh H., Kim B.M., Kim C.Y., Jeon C., Jung C.W. 2007. Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. Clin Immunol 25:
257–267.
Kim J.Y., Kang J.S., Kim H.M., Kim Y.K., Lee H.K., Song S., Hong J.T., Kim Y, Han S.B. 2009. Inhibition of phenotypic and functional maturation of dendritic cells by manassantin A. J Pharmacol Sci 109:583–592.
Klapper J.A., Downey S.G., Smith F.O., Yang J.C., Hughes M.S., Kammula U.S., Sherry R.M., Royal R.E., Steinberg S.M., Rosenberg S. 2008. High-dose
interleukin-2 for the treatment of metastatic renal cell carcinoma: A retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 113: 293-301.
Kobayashi T., Shinohara H., Toyoda M., Iwamoto S., Tanigawa N. 2007. Regression of lymph node metastases by immunotherapy using autologous breast tumor-lysate pulsed dendritic cells: report of a case. Surg Today 31: 513-516
Larmonier N., Fraszczak J., Lakomy D., Bonnotte B., Katsanis E. 2009. Killer dendritic cells and their potential for cancer immunotherapy. Cancer Immunol Immunother 59: 1-11.
Lepisto A.J., Moser A.J., Zeh H., Lee K., Bartlett D., McKolanis J.R., Geller B.A., Schmotzer A., Potter D.P., Whiteside T., Finn O.J., Ramanathan R.K. 2008. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther 6:
955–964.
Lotem M., Zhao Y., Riley J., Hwu P., Morgan R.A., Rosenberg S.A,. Parkhurst M.R.
2006. Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors. J Immunother 29: 616-627.
Lutz M.B., Schuler G. 2002. Immature, semi-mature and fully mature dendritic cells:
which signals induce tolerance or immunity? Trends Immunol 23:445-449 MacEwen E.G. 1990. Spontaneous tumors in dogs and cats: models for the study of
Cancer biology and treatment. Cancer Metastasis Rev 9: 125–136.
Mahnke K., Knop J., Enk A.H. 2003. Induction of tolerogenic DCs: 'you are what you eat' Trends Immunol 24:646-651.
Maraskovsky E., Chen W.F., Shortman K. 1989. IL-2 and IFN- are two necessary lymphokines in the development of cytolytic T cells. J Immunol 143: 1210-1214.
Marconato L., Romanelli G., Stefanello D., Giacoboni C., Bonfanti U., Bettini G., Finotello R., Verganti S., Valenti P., Ciaramella L., Zini E. 2009. Prognostic factors for dogs with mammary inflammatory carcinoma: 43 cases (2003-2008). J Am Vet Med Asso. 235:967-972.
Märten A., Flieger D., Renoth S., Weineck S., Albers P., Compes M., Schöttker B., Ziske C., Engelhart S., Hanfland P., Krizek L., Faber C., von Ruecker A., Müller S., Sauerbruch T., Schmidt-Wolf I.G. 2002. Therapeutic vaccination against metastatic
renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. Cancer Immunol Immunother 51: 637-644.
Merad M., Sugie T., Engleman E., Fong L. 2002. In vivo manipulation of dendritic cells to induce therapeuticimmunity. Blood 99: 1676-1682.
Morse M.A., Zhou L., Tedder T., Lyerly H., Smith C. 1997. Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage- colony-stimulating factor, interleukin-4, and tumor necrosis factor-alpha for use in cancer. Immunotherapy 226: 6-16.
Morse M.A., Coleman R.E., Akabani G., Niehaus N., Coleman D., Lyerly H.K., 1999.
Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 59: 56-58.
Morse MA, Deng Y, Coleman D, Hull S, Kitrell-Fisher E, Nair S, Schlom J, Ryback M-E, Lyerly HK. 1999. A phase Ⅰ study of active immunotherapy with
carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Crinical Cancer Res 5: 1331-1338.
Mulé J. 2000. Dendritic cells at the clinical crossroads. J Clin Invest. 105: 707-708.
Nakano O., Sato M., Naito Y., Suzuki K., Orikasa S., Aizawa M., Suzuki Y., Shintaku I., Nagura H., Ohtani H. 2001. Proliferative activity of intratumoral CD8(+)
T-lymphocytes as a prognostic factor in human renal cell carcinoma:
clinicopathologic demonstration of antitumor immunity. Cancer Res 61:5132-5136.
Nathan C.F., Hibbs J., Jr. 1991. Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr Opin Immunol 3: 65-70.
Nelson E.L., Strobl S., Subleski J., Prieto D., Kopp W.C., Nelson P.J. 1999. Cycling of human dendritic cell effector phenotypes in response to TNF-alpha: modification of
the current 'maturation' paradigm and implications for in vivo immunoregulation.
FASEB J 13: 2021-2030
Oba M., Yano S., Shuto T., Suico M.A., Eguma A., Kai H. 2008. IFN-γ down-regulates Hsp27 and enhances hyperthermia-induced tumor cell death in vitro and tumor suppression in vivo. Int J Oncology 32: 1317-1324.
Otto U., Conrad S., Schneider A.W., Klosterhalfen H. 1988. Recombinant interferon gamma in the treatment of metastatic renal cell carcinoma. Results of a phase II trial.
Arzneimittelforschung 38: 1658-1660.
Overwijk W.W., Theoret M.R., Restifo N.P. 2000. The future of interleukin-2:
Enhancing therapeutic anticancer vaccines. Cancer J Sci Am 1: 76-80.
Pagès F., Berger A., Camus M., Sanchez-Cabo F., Costes A., Molidor R., Mlecnik B., Kirilovsky A., Nilsson M. Damotte D., Meatchi T., Bruneval P., Cugnenc PH., Trajanoski Z., Fridman WH., Galon J. 2005. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353:2654-2666.
Palmer D.H., Midgley R.S., Mirza N., Torr E.E., Ahmed F., Steele J.C., Steven N.M., Kerr D.J., Young L.S., Adams D.H. 2009. A phase II study of adoptive
immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology 49: 124–32.
Pedersen A.E., Thorn M., Gad M., Walter M.R., Johnsen H.E., Gaarsdal E., Nikolajsen K., Buus S., Claesson M.H., Svane I.M. 2005. Phenotypic and functional
characterization of clinical grade dendritic cells generated from patients with advanced breast cancer for therapeutic vaccination. Scand J Immunol 61:147–156.
Presicce P., Taddeo A., Conti A., Villa M.L., Bella S.D. 2008. Keyhole limpet
hemocyanin induces the activation and maturation of human dendritic cells through the involvement of mannoce receptor. Molecular Immunology 45:1136-1145.
Recombinant Human Interferon Gamma (S-6810) Research Group on Renal Cell
Carninoma 1987. Phase II study of recombinant human interferon gamma (S-6810) on renal cell carcinoma. Summary of two collaborative studies. Cancer. 60:929-933.
Redman B.G., Chang A.E., Whitfield J., Esper P., Jiang G., Braun T., Roessler B., Mulé J.J. 2008. Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma. J Immunother 31: 591-598.
Ribatti D., Nico B., Pezzolo A., Vacca A., Meazza R., Cinti R., Carlini B., Parodi F., Pistoia V., Corrias M.V. 2006. Angiogenesis in a human neuroblastoma xenograft model: Mechanisms and inhibition by tumour-derived interferon-gamma. Br J Cancer 94: 1845-1852.
Riggs J.L., McAllister R.M., Lennette E.H.1974. Immunofluorescent studies of RD-114 virus replication in cell culture. J Gen Virol 25:21–29.
Rivoltini L., Gambacorti-Passerini C., Squadrelli-Saraceno M., Grosso M.I., Cantù G., Molinari R., Orazi A., Parmiani G. 1990. In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors. Cancer Res 50: 5551-5557.
Romani N., Reider D., Heuer M., Ebner S., Kämpgen E., Eibl B., Niederwieser D., Schuler G. 1996. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 196: 137-151.
Sad S., Marcotte R., Mosmann T.R. 1995. Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines.
Immunity 2: 271.
Saleh M., Jonas N.K., Wiegmans A., Stylli S.S. 2000. The treatment of established intracranial tumors by in situ retroviral IFN-γ transfer. Gean Therapy 7: 1715-1724.
Sallusto F., Lanzavecchia A. 1994. Efficient presentation of soluble antigen by cultured
human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus iuterleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179: 1109-1118.
Sato E., Olson S.H., Ahn J., Bundy B., Nishikawa H., Qian F., Jungbluth A.A., Frosina D., Gnjatic S., Ambrosone C., Kepner J., Odunsi T., Ritter G., Lele S., Chen Y.T., Ohtani H., Old L.J., Odunsi K. 2005. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci 102:18538-18543.
Slos P., De Meyer M., Leroy P., Rousseau C., Acres B. 2001. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: Induction of CD8(+) T-cell immunity and NK activity. Cancer Gene Ther. 8: 321-332.
Smyth M.J, Kelly J.M. 1999. Accessory function for NK1.1+ natural killer cells producing interferon-gamma in xenospecific cytotoxic T lymphocyte differentiation.
Transplantation 68: 840-843.
Stainman R.M, Dhodapkar M. 2001. Active immunization against cancer with dendritic cells: the near future. Int J Cancer 94: 459-473.
Sugiura K., Wijewardana V., Fujimoto M., Akazawa T., Yahata M., Mito K., Hatoya S., Inoue N., Inaba T. 2010. Effect of IL-12 on canine dendritic cell maturation
following differentiation induced by granulocyte-macrophage CSF and IL-4. Vet Immunol Immunopathol 137:322-326.
Svane I.M., Pedersen A.E., Johnsen H.E., Nielsen D., Kamby C., Gaarsdal E.,
Nikolajsen K., Buus S., Claesson M.H. 2004. Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase Ⅰ study.
Cancer Immunol Immunother 53: 633-641.
Wang Y.S., Chi K.H., Liao K.W., Liu C.C., Cheng C.L., Lin Y.C., Cheng C.H., Chu R.M.